Antimicrobial needlefree

Baxter Healthcare Corporation today announced that it received 510(k) clearance for expanded labeling for the first antimicrobial needleless intravenous (IV) connector, V-Link Luer-activated device (LAD) with VitalShield protective coating.

Launched earlier this year, V-Link with VitalShield has now been shown to kill at least 99.99 percent of six common pathogens known to cause catheter-related bloodstream infections. The U.S. Food and Drug Administration (FDA) cleared expanded labeling for V-Link with VitalShield based on V-Link’s ability to combat three additional pathogens: vancomycin-resistant Enterococcus faecalis (VRE), Escherichia coli (E. coli) and Staphylococcus epidermidis (coagulase negative). These three pathogens improve upon the previously cleared labeling, which included methicillin-resistant Staphylococcus aureus (MRSA), Pseudomonas aeruginosa and Enterobacter cloacae.

Click here for the full story on iStoclAnalysist.

Click here for the V-Link product page.

Other stories

• Refeeding syndrome
• PICC placement kit
• Blood cultures
• Older blood increases infection risk
• Community IV’s in the news
• Vascular access complications
• High tech clean rooms
• Outpatient IV for heart failure
• Topical local anaesthesia review
• BBraun silver needlefree
• Electronic infection surveillance
• Intravenous therapy safety assessment

Add IVTEAM to Technorati Favorites